PrimeEnergy (NASDAQ:PNRG) Major Shareholder Rothschild Robert De Sells 13,274 Shares of Stock

Bristol Myers Squibb reported a patient death in a Phase 1 trial for its CAR-T therapy targeting multiple sclerosis. The patient had pre-existing complications and died from septic pneumonia. The company noted this may impact the therapy's safety assessment. The incident raises concerns about CAR-T therapy's safety and regulatory challenges in autoimmune treatments.

Boeing 777F production halted for nearly two months due to a dispute with supplier Vaero over wing components, costing Boeing up to $6.5M per day. The 777F has 38 unfilled orders, with a backlog of about 31 aircraft. The FAA extended production through 2030, allowing up to 35 additional 777Fs. Boeing delivered 21 777Fs in 2026, with demand continuing despite the transition to the 777-8F.

Eli Lilly presented Phase 1 data for its investigational ADC sofetabart mipitecan (Sofe-M) plus bevacizumab in platinum-sensitive ovarian cancer, showing a 79% objective response rate and 100% disease control rate. The study included 33 patients, with responses consistent across prior treatments. Sofe-M demonstrated a safety profile consistent with known profiles of each medicine. The company is conducting three global Phase 3 trials for Sofe-M in ovarian cancer.

Orion Corporation (OEC) reported interim Phase III results showing that darolutamide, combined with ADT and RT, reduced the risk of metastasis or death by 58% in high-risk recurrent prostate cancer. The 4-year metastasis-free survival rate was 95% compared to 88%. Darolutamide is not yet approved for this use.

Eli Lilly (LLY) presented Phase 1 data for its investigational drug sofetabart mipitecan (Sofe-M) plus bevacizumab, showing a 79% objective response rate and 100% disease control rate in platinum-sensitive ovarian cancer. The study included 33 patients, with responses consistent across FRα expression levels and prior PARP inhibitor exposure. Sofe-M is being studied in multiple Phase 3 trials under the FRAmework-01 program.

Eli Lilly's experimental drug, sofetabart mipitecan (Sofe-M), showed promising results in a Phase 1 study for ovarian cancer, with a 100% disease control rate in patients. Sofe-M, an FRα-targeting antibody-drug conjugate, is being studied in multiple Phase 3 trials. The company aims to address the unmet need in platinum-sensitive ovarian cancer treatment.